Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 14;100(17):adv00289.
doi: 10.2340/00015555-3622.

Increased Risk of Squamous Cell Carcinoma of the Skin and Lymphoma Among 5,739 Patients with Bullous Pemphigoid: A Swedish Nationwide Cohort Study

Zeyad Albadri  1 , Kristofer Thorslund, Henrike Häbel, Oliver Seifert, Carina Grönhagen
Affiliations

Increased Risk of Squamous Cell Carcinoma of the Skin and Lymphoma Among 5,739 Patients with Bullous Pemphigoid: A Swedish Nationwide Cohort Study

Zeyad Albadri et al. Acta Derm Venereol. .

Abstract

Evidence about the association of bullous pemphigoid and the risk of cancer is conflicting. Patients diagnosed with bullous pemphigoid (n = 5,739) between 2005 and 2016 were matched with a control cohort from the general population (n = 17,168) to estimate their overall and specific risk of cancer. The risk of squamous cell cancer of the skin (cSCC) was increased in patients with bullous pemphigoid (hazard ratio (HR) 1.3; 95% confidence interval (CI) 1.1-1.6). The risk of lymphoma within one year after bullous pemphigoid diagnosis was also increased (HR 3.1; 95% CI 1.3-7.6). While overall cancer risk prior to diagnosis of bullous pemphigoid was similar in cases and controls (prevalence odds ratio (POR) 1.0; 95% CI 0.9-1.0), the risk of male genital cancer within one year prior to diagnosis of bullous pemphigoid was lower in cases (POR 0.4; 95% CI 0.2-0.8). Clinicians must be aware of the increased risk of cSCC and lym-phoma in patients with bullous pemphigoid.

Keywords: autoimmune diseases; bullous pemphigoid; epidemiology; malignancy; skin diseases; cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007; 33: 67–77. - PubMed
    1. Phan K, Goyal S, Murrell DF. Association between bullous pemphigoid and psoriasis: Systematic review and metaanalysis of case-control studies. Austral J Dermatol 2019; 60: 23–28. - PubMed
    1. Davis AL, Bhogal BS, Whitehead P, Frith P, Murdoch ME, Leigh IM, et al. . Lichen planus pemphigoides: its relationship to bullous pemphigoid. Br J Dermatol 1991; 125: 263–271. - PubMed
    1. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. Eur Acad Dermatol Venereol 2014; 28: 1133–1140. - PubMed
    1. Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol 2018; 154: 1152–1158. - PMC - PubMed